In clinical trials, success hinges not just on protocol design and quality data but on choosing the right investigative sites and engaging them effectively. Here are four key reasons why strategic site selection is critical for maximizing value in your clinical trials.

Discover how CRC leveraged our proprietary driving simulator to swiftly complete a next-day effects study in support of a multinational Pharma Company's NDA submission. This case study showcases our ability to navigate complex clinical challenges under tight timelines, finishing 11 days ahead of schedule and exceeding project expectations.

Since 2018, more than 30 drugs with the potential to impair driving ability have been approved without a dedicated driving study, despite clearly meeting the FDA criteria for such studies based on a conservative application of these criteria.

On World Mental Health Day, we reflect on the strides being made in mental health care and the hope that new therapies bring. A recent breakthrough—a safer treatment for agitation in schizophrenia and bipolar disorders—embodies this progress. CRC is proud to have supported the clinical trials that led to FDA approval, staying true to our mission of improving patients’ lives.

Learn how CRC’s proactive approach and real-time data oversight supported the FDA approvals of two novel migraine treatments. Download the full case study to discover the strategies CRC implemented to overcome challenges and ensure the successful capture of primary endpoint data at critical timepoints.

Cognitive Research Corporation (CRC), a leading CNS-focused clinical research organization, proudly announces the addition of four distinguished professionals to its medical leadership team: Dr. Albena Patroneva, Dr. Mark Versavel, Dr. Sandeep Vaishnavi, and Dr. Djouher Hough. These accomplished experts bring deep specialization in neurology, psychiatry, analgesia, and psychedelic research, further enhancing CRC’s ability to deliver advanced scientific guidance and innovative solutions in clinical research.

Discover how CRC’s approach helped a biopharma company secure FDA approval for a novel treatment targeting acute agitation in schizophrenia and bipolar disorders. With strong site relationships, rigorous rater training, and expert regulatory guidance, the project team successfully navigated complex conditions, including the challenges posed by the COVID-19 pandemic.

Discover how CRC’s expertise in clinical trial management supported the FDA approval of a novel formulation for schizophrenia treatment. Download the full case study to explore the challenges faced, proactive solutions implemented, and the strategic approach that delivered results on time and on budget.

Backed by select partnerships with Phase I Specialty Units and a tenured team, CRC consistently reaches milestones under tight clinical timelines in early phase studies. Learn how our strategic approach and robust collaboration led to dosing the last subject two weeks ahead of schedule while maintaining data quality.

Learn how CRC partnered with an emerging biotech to overcome tight clinical timelines and successfully achieve the First Patient In milestone just 6 weeks from the written award. This case study showcases CRC’s rapid alignment, problem-solving capabilities, and operational excellence that not only met the sponsor’s stringent deadline but also boosted stakeholder confidence.